{"task_id": "07e698569ba12d67", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 209/464)", "text": "flection\nMANAGEMENT (CONT\u2019D)\n198\nColorectal Cancer\n\n--- Page 220 ---\nPATHOPHYSIOLOGY (CONT\u2019D)\nColon cancer\nRectal cancer\nMetastasis\nLiver\nLiver and lung\nAdjuvant\ntreatments\nChemo\nRT and chemo\nMOLECULAR SEQUENCE FOR DEVELOPMENT OF\nCOLON CANCER\nthe Vogelstein model of carcino\ngenesis developed based on analysis of FAP lesions.\nNormal epithelium ! loss of 5q (e.g. APC, b catenin)\nover decades ! adenoma development ! loss of\n18q (e.g. k ras) over 2 5 years ! late adenoma !\nloss of 17p (e.g. p53) over 2 5 years ! early cancer\n! loss of 8p ! late cancer\nMICROSATELLITE INSTABILITY (MSI)\nmay either\nbe inherited as in HNPCC or spontaneous (15% of\nsporadic colon cancers). MSI is characterized by a\ndecreased response to 5 fluorouracil based adjuvant\nchemotherapy but improved prognosis\nK RAS MUTATION\nabout 40% of colon cancer has\nmutation in KRAS, which plays a key role in signal\ntransduction downstream of EGFR. Tumors with wild\ntype K ras have been shown to be more responsive to\nEGFR based\ntherapy\n(panitumumab,\ncetuximab)\ncompared to mutant. This makes biologic sense as a\nmutated KRAS could continue to activate cell prolif\neration despite inhibition of EGFR\nCLINICAL FEATURES\nLOCOREGIONAL\nbowel habit D, hematochezia,\nparadoxical diarrhea, tenesmus, abdominal pain,\niron deficiency anemia\nMETASTATIC\nRUQ pain, dyspnea\nCONSTITUTIONAL\nweight loss, anorexia, fatigue\nOTHER\nStreptococcus bovis bacteremia and Clostri\ndium septicum sepsis; colorectal cancer in 16 32% of\npatients with S. bovis bacteremia\nSTAGING\nTNM STAGING\nT stage\n\u0002 T1=invades submucosa\n\u0002 T2=invades muscularis propria\n\u0002 T3=invades subserosa or non peritonealized\npericolic tissues\n\u0002 T4=perforation of visceral peritoneum or directly\ninvades into adjacent structure (bowel, bladder,\nuterus, pelvic wall)\nN stage (mesenteric ! supraclavicular)\n\u0002 N1=1 3 LN\n\u0002 N2=\u00054 LN\nM stage (liver, lung, bone, brain)\n\u0002 M1=distant metastasis\nSTAGING (CONT\u2019D)\nSTAGE GROUPINGS\nStage\nTNM @=any\nFrequency\n5 year\nsurvival\nI\nT1 2N0M0\n15%\n90%\nIIA\nT3N0M0 g\n20%\n85%\nIIB\nT4N0M0\n70%\nIIA\nT1 2N1M0\n80%\nIIIB\nT3 4N1M0g\n40%\n60%\nIIIC\nT@N2M0\n45%\nIV\nT@N@M1\n25%\n5%\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, AST, ALT, ALP, bilir\nubin, INR, PTT, albumin, lipase, CEA, CA19 9\n\u0002\nIMAGING\nbarium enema, CT abd, CXR, MRI, and\nendorectal U/S in rectal cancer\n\u0002\nBIOPSY\ncolonoscopy with biopsy, laparoscopy,\nlaparotomy\nMANAGEMENT OF COLON CANCER\nSTAGE I\nsurgical resection only\nSTAGE\nII\nsurgical\nresection.\nAdjuvant\nche\nmotherapy (capecitabine, 5 fluorouracil leucovorin,\nconsider FOLFOX if high risk) may be given if adverse\nprognostic features (T4, perforation, obstruction,\npoorly differentiated, signet ring cell and mucinous\nhistology, lymphovascular invasion, inadequate LN\nsampling <12)\nSTAGE III\nsurgical resection + adjuvant che\nmotherapy (FOLFOX is the first choice. Other possi\nbilities include capecitabine, 5 fluorouracil leucov\norin, infusional 5 fluorouracil if patient is not fit or\nhas contraindications to oxaliplatin)\nSTAGE IV\nif metastasis limited to liver and poten\ntially resectable, consider liver resection plus perio\nperative chemotherapy. Radiofrequency ablation\ncould be considered if patient unfit for surgery. If\nnon resectable disease, palliative chemotherapy\n(FOLFIRI bevacizumab\nor\nFOLFOX bevacizumab.\nCapecitabine or 5 fluorouracil/LV if patient unfit. Ral\ntitrexed if 5 fluorouracil intolerant. Cetuximab irino\ntecan or single agent panitumumab in third line if\nKRAS wild type)\nRelated Topics\nCancer Screening (p. 222)\nChemotherapy Induced Diarrhea (p. 231)\nOral Mucositis (p. 230)\nHematochezia (p. 120)\nHereditary Cancers (p. 224)\nColorectal Cancer\n199", "text_length": 3620, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 209/464)", "type": "chunk", "chunk_index": 208, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.533643", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.534510", "status": "complete", "chunks_added": 2}